Prediction of Mortality in Patients on Peritoneal Dialysis Based on the Fibrinogen Mannosylation

Cells. 2023 Jan 17;12(3):351. doi: 10.3390/cells12030351.

Abstract

As we already reported, fibrinogen fucosylation emerged as a prognostic marker of peritoneal membrane function in end-stage renal disease (ESRD) patients on peritoneal dialysis. After a follow-up period of 18 months, we estimated the ability of employed lectins, as well as other biochemical parameters, to serve as mortality predictors in these patients. Following a univariate Cox regression analysis, ferritin, urea clearance, residual diuresis, hyperglycemia, and an increase in the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors, but additional multivariate Cox regression analysis pointed only to glucose concentration and GNL as mortality predictors. Higher signal intensity obtained with GNL in patients that died suggested the importance of paucimannosidic/highly mannosidic N-glycan structures on fibrinogen as factors that are related to unwanted cardiovascular events and all-cause mortality and can possibly be seen as a prediction tool. Altered glycan structures composed of mannose residues are expected to affect the reactivity of mannosylated glycoproteins with mannose-binding lectin and possibly the entire cascade of events linked to this lectin. Since patients with ESRD are prone to cardiovascular complications and the formation of atherosclerotic plaques, one can hypothesize that fibrinogen with increasingly exposed mannose residues may contribute to the unwanted events.

Keywords: CKD; ESRD; N-glycans; glycosylation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Fibrinogen
  • Hemostatics*
  • Humans
  • Kidney Failure, Chronic*
  • Lectins
  • Mannose
  • Peritoneal Dialysis*
  • Polysaccharides / chemistry

Substances

  • Fibrinogen
  • Mannose
  • Lectins
  • Polysaccharides
  • Hemostatics

Grants and funding

This work was supported by the Ministry of Education, Science and Technological Development of the Republic of Serbia (Grant no. 451-03-68/2022-14/200019) and the Bilateral Cooperation project with the Republic of Slovakia (Grant no. 337-00-107/2019-09/12), grant APVV SK-SRB-21-0046, grant VEGA 2/0120/22 and grant APVV-20-0243. This publication is the result of the project implementation CEMBAM–Centre for Medical Bio-Additive Manufacturing and Research, ITMS2014+: 313011V358, supported by the Operational Programme Integrated Infrastructure funded by the European Regional Development Fund.